Russell Investments Group Ltd. Trims Stock Position in Repligen Co. (NASDAQ:RGEN)

Russell Investments Group Ltd. cut its position in shares of Repligen Co. (NASDAQ:RGENGet Rating) by 17.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,827 shares of the biotechnology company’s stock after selling 11,887 shares during the period. Russell Investments Group Ltd. owned approximately 0.11% of Repligen worth $10,874,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. HM Payson & Co. purchased a new position in Repligen during the fourth quarter worth about $26,000. Confluence Wealth Services Inc. purchased a new stake in Repligen during the 4th quarter worth approximately $27,000. Sageworth Trust Co of South Dakota purchased a new stake in Repligen during the 4th quarter worth approximately $46,000. Rise Advisors LLC purchased a new stake in Repligen during the 4th quarter worth approximately $52,000. Finally, UMB Bank N A MO purchased a new stake in Repligen during the 4th quarter worth approximately $59,000. 86.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on RGEN shares. KeyCorp upped their target price on shares of Repligen from $245.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday. Craig Hallum cut their target price on shares of Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. SVB Leerink upped their target price on shares of Repligen from $220.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday. Stephens upped their target price on shares of Repligen from $220.00 to $275.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, UBS Group began coverage on shares of Repligen in a report on Wednesday, July 20th. They set a “buy” rating and a $213.00 price target for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average price target of $276.00.

Insider Transactions at Repligen

In other news, insider Christine Gebski sold 3,357 shares of Repligen stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $243.01, for a total transaction of $815,784.57. Following the sale, the insider now owns 30,735 shares in the company, valued at $7,468,912.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Christine Gebski sold 3,357 shares of Repligen stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $243.01, for a total transaction of $815,784.57. Following the sale, the insider now owns 30,735 shares in the company, valued at $7,468,912.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO James Bylund sold 2,000 shares of Repligen stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $240.40, for a total value of $480,800.00. Following the sale, the chief operating officer now owns 9,733 shares in the company, valued at approximately $2,339,813.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,874 shares of company stock worth $8,911,739. Corporate insiders own 1.10% of the company’s stock.

Repligen Trading Up 1.2 %

Shares of Repligen stock opened at $246.27 on Friday. The company has a fifty day simple moving average of $175.20 and a 200-day simple moving average of $174.08. Repligen Co. has a 12-month low of $137.21 and a 12-month high of $327.32. The stock has a market cap of $13.40 billion, a price-to-earnings ratio of 88.91 and a beta of 1.07.

Repligen (NASDAQ:RGENGet Rating) last released its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.19. Repligen had a net margin of 20.47% and a return on equity of 11.18%. The company had revenue of $207.63 million during the quarter, compared to the consensus estimate of $189.06 million. During the same quarter in the prior year, the firm posted $0.79 earnings per share. Repligen’s revenue for the quarter was up 27.4% on a year-over-year basis. On average, analysts forecast that Repligen Co. will post 3.21 earnings per share for the current fiscal year.

Repligen Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.